KODKodiak Sciences
About Kodiak Sciences
Kodiak Sciences (NASDAQ:KOD) is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutics to treat high prevalence retinal diseases. Kodiak's flagship project involves creating novel biologics with the potential to provide durable, long-term efficacy with fewer injections for patients, addressing a significant unmet need in fields such as macular degeneration and diabetic eye diseases. The company's objective is to revolutionize retinal medicine and improve the lives of millions worldwide by advancing their pipeline of therapeutic candidates through clinical trials and bringing them to market.
What is KOD known for?
Snapshot
Public US
Ownership
2005
Year founded
116
Employees
Palo Alto, United States
Head office
1 of 2
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Palo Alto, US
Products and/or services of Kodiak Sciences
- KSI-301, an investigational anti-VEGF therapy designed for the treatment of retinal diseases including age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.
- Antibody Biopolymer Conjugate platform, a proprietary technology aimed at enhancing the durability and efficacy of therapeutic antibodies in ophthalmology.
- Research and development focused on novel biologics for the treatment of high-prevalence retinal diseases, leveraging advanced molecular engineering and drug delivery techniques.
- Preclinical programs targeting new mechanisms of action for the treatment of retinal diseases, aiming to address unmet needs beyond VEGF inhibition.
- Proprietary manufacturing process designed to produce biopolymer-conjugated molecules at scale, ensuring quality and consistency for clinical and commercial supply.
- Collaboration with global pharmaceutical companies and academic institutions to advance the research, development, and commercialization of transformative therapies for ophthalmic diseases.
Kodiak Sciences executive team
- Dr. Victor Perlroth M.D.Co-Founder, Chairman, CEO & President
- Mr. John A. Borgeson CPA, M.B.A.Executive VP, CFO & Secretary
- Dr. Dolly S. Chang M.D., M.P.H., Ph.D.Chief Scientific Officer
- Dr. Hong Liang Ph.D.Senior Vice President of Development
- Dr. Stephen Raillard Ph.D.Senior Vice President of Chemical Development & Manufacturing
- Ms. Almas Qudrat M.Sc.Chief Quality Officer
- Dr. J. Pablo Velazquez-Martin M.D.Chief Medical Officer
- Dr. Laurent Ducay Ph.D.Senior VP of Biologics Development & Manufacturing